Amgen (NASDAQ:AMGN) Earns Neutral Rating from Cantor Fitzgerald

Key Points

• Cantor Fitzgerald reiterated a "neutral" rating on Amgen with a $350 price target (≈2.94% upside); MarketBeat's consensus rating is "Hold" with a $355 consensus target.
• Q4 results beat expectations: Amgen reported EPS of $5.29 (vs. $4.76 est.) and revenue of $9.87B (vs. $9.46B est.), and set FY2026 guidance at 21.600–23.000 EPS.
• Amgen announced positive Phase‑3 topline data for subcutaneous TEPEZZA (77% proptosis response), which could expand commercial upside, but investor reaction was mixed and competitive/implementation concerns may increase near‑term stock volatility.

Amgen (NASDAQ:AMGN - Get Free Report)'s stock had its "neutral" rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Wednesday,Benzinga reports. They presently have a $350.00 price objective on the medical research company's stock. Cantor Fitzgerald's price objective points to a potential upside of 2.94% from the company's current price.

A number of other equities analysts have also recently commented on the company. Daiwa Securities Group raised their target price on Amgen from $370.00 to $410.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. Rothschild & Co Redburn upped their price target on Amgen from $180.00 to $200.00 and gave the stock a "sell" rating in a research report on Wednesday, February 18th. UBS Group raised their price objective on Amgen from $380.00 to $390.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. HSBC reiterated a "buy" rating and set a $425.00 price objective on shares of Amgen in a research note on Wednesday, December 10th. Finally, Mizuho increased their target price on shares of Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $355.00.

Amgen Stock Performance

Shares of AMGN opened at $340.00 on Wednesday. The business has a fifty day moving average of $363.28 and a 200 day moving average of $334.04. Amgen has a one year low of $261.43 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $183.28 billion, a P/E ratio of 23.89, a PEG ratio of 3.45 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts' consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts' expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm's revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts anticipate that Amgen will post 20.62 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AMGN. Old North State Trust LLC grew its stake in Amgen by 21.6% during the fourth quarter. Old North State Trust LLC now owns 2,568 shares of the medical research company's stock valued at $841,000 after acquiring an additional 456 shares in the last quarter. J. Derek Lewis & Associates Inc. bought a new stake in shares of Amgen in the fourth quarter worth about $269,000. Purpose Unlimited Inc. bought a new stake in shares of Amgen in the fourth quarter worth about $1,299,000. Cornerstone Planning LLC purchased a new stake in shares of Amgen in the fourth quarter worth about $2,155,000. Finally, Rockefeller Capital Management L.P. boosted its stake in Amgen by 27.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 642,161 shares of the medical research company's stock valued at $210,186,000 after buying an additional 138,577 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Phase‑3 topline: Amgen announced TEPEZZA subcutaneous OBI met primary and key secondary endpoints with a 77% proptosis response — potentially broadening access and driving future revenue upside for an already marketed franchise. AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA
• Positive Sentiment: Analyst praise and buy‑case: Commentary and pieces (e.g., Seeking Alpha) frame Amgen as the better buy after the data, highlighting competitive advantages versus rival programs. Amgen's Thyroid Eye Disease Data Rocks Rival Viridian...
• Positive Sentiment: RBC raises price target to $370 and maintains Outperform — a near‑term analyst upgrade that supports upside thesis. RBC Capital Adjusts Amgen Price Target
• Neutral Sentiment: Competitive nuance: Stifel notes Amgen’s topline beats Viridian on proptosis response but says Viridian’s SC injection profile could still differentiate commercially — competition remains meaningful. Stifel sees path towards differentiation for Viridian...
• Neutral Sentiment: Investor interest and valuation context: Zacks and Yahoo pieces flag heavy search/interest and reiterate Amgen’s value metrics and sector performance — useful for longer‑term framing but not immediate catalysts. Here's Why Amgen (AMGN) is a Strong Value Stock
• Negative Sentiment: Mixed market reaction: Several outlets note AMGN shares fell intraday despite the positive TEPEZZA data, indicating investors are weighing adoption, reimbursement, injector logistics and any near‑term revenue/phasing uncertainty. Amgen Posts 77% Response In Thyroid Eye Disease Study
• Negative Sentiment: Volatility in peer stocks: Rival Viridian plunged after Amgen’s results, underscoring sector re‑rating risk and competitive uncertainty that can spill back into Amgen’s short‑term stock volatility. Viridian Therapeutics stock tumbles after Amgen Tepezza data

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.